Related Experiment Video

Updated: Aug 21, 2026

Development and Application of Rapamycin-regulated Tyrosine Phosphatases
06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Mammalian target of rapamycin inhibition

Janice P Dutcher1

  • 1Comprehensive Cancer Center, Our Lady of Mercy Medical Center, Bronx, New York 10466, USA. jpd4401@aol.com

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|September 28, 2004
PubMed

Insights

Mammalian target of rapamycin (mTOR) inhibition is a promising antitumor therapy. It effectively blocks cell cycle progression and shows efficacy in preclinical models and clinical trials for metastatic renal cell cancer.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cell Biology

Background:

  • The mammalian target of rapamycin (mTOR) is a crucial kinase regulating cell growth, proliferation, and vital cellular functions.
  • mTOR influences translation initiation, actin organization, tRNA synthesis, ribosome biogenesis, and protein degradation.
  • Inhibition of mTOR disrupts the cell cycle, specifically blocking the G1 to S phase transition.

Purpose of the Study:

  • To evaluate the potential of mTOR inhibition as an antitumor therapeutic strategy.
  • To investigate the efficacy of mTOR inhibitors in preclinical cancer models and ongoing clinical trials.
  • To explore the specific susceptibility of renal cell cancer to mTOR inhibition.

Main Methods:

  • Preclinical evaluation using cell lines and xenograft models.
  • Analysis of clinical trial data for patients with metastatic renal cell cancer.
  • Investigation of molecular pathways affected by mTOR inhibition, including translation and HIF-1alpha gene expression.

Main Results:

  • Preclinical studies demonstrated significant inhibition of tumor growth.
  • Clinical trials have shown tumor regression and prolonged stabilization in metastatic renal cell cancer.
  • Renal cell cancer exhibits particular susceptibility due to translation inhibition and enhanced HIF-1alpha expression.

Conclusions:

  • mTOR inhibition represents a key pathway with significant potential in antitumor therapy.
  • Agents targeting mTOR are under active clinical investigation for various cancers.
  • Renal cell cancer may be a prime candidate for mTOR-targeted therapies.

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...